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ABSTRACT 
In a single arm pilot study, 47 post-menopausal women affected by vulvovaginal atrophy 
(VVA) were enrolled. All women underwent vaginal health index score (VHIS) evaluation 
and completed the female sexual function index (FSFI) questionnaire at baseline evaluation 
(T0) and following 15 days of vaginal cream treatment with one application per day (T1). 
Following treatment there was a significant improvement of all VHIS parameters and total 
score (p<0.0001). Similarly, there was a significant improvement of 4 FSFI domains 
(lubrication, orgasm, satisfaction and pain) and total score (p=0.001). None of the patients 
reported any local or systemic side effect during the treatment.  
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Commented [AL1]: We used the term “single arm pilot 
study” both in the title of the study and the body of the text, 
as suggested by Reviewer 2. 
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Introduction 
 Accumulating evidence suggests that vulvovaginal atrophy (VVA) is strongly 
associated with female sexual dysfunction (FSD) among sexually active postmenopausal 
women [1, 2].  
Visnadine, an active ingredient of the fruit of Ammi visnaga, showed powerful 
vasodilatory activity due to the inhibitory effects on voltage-gated L-type Ca2+ channels, and 
has been found to ameliorate female sexual arousal disorder [3]. Furthermore, 
prenylflavonoids and phytoestrogens play a potent role as estrogen receptor (ER)-alpha 
selective agonist [4], thus they may counteract the effects of postmenopausal estrogen loss. 
Finally, a vaginal cream containing bovine colostrum has been shown to be effective in 
relieving vaginal dryness and other VVA symptoms in postmenopausal women, after 8 weeks 
of treatment [5]. 
Based on this information, we aimed to assess the safety and efficacy of a new vaginal 
cream containing visnadine, prenylflavonoids and bovine colostrum on Vaginal Health Index 
Score (VHIS) and Female Sexual Function Index (FSFI) in a cohort of postmenopausal 
sexually active women affected by VVA. 
 
Methods  
 A prospective single arm pilot study (ClinicalTrials.gov ID: NCT03281655) was 
undertaken after institutional review board (IRB) approval, between December 2016 and May 
2017 at the Unit of Gynecology and Obstetrics, Department of Human Pathology in 
Adulthood and Childhood “G. Barresi”, University of Messina (Messina, Italy). We 
consecutively enrolled post-menopausal women affected by VVA, excluding patients affected 
by relevant comorbidities (chronic cardiovascular, immune, endocrine and metabolic diseases 
and cancers), smokers and who used any other kind of pharmacologic treatment (including the 
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substances tested in this study) in the previous 3 months. VVA was defined as self-reporting at 
least one of the following in the past 4 weeks: vaginal dryness, vaginal itching, vaginal 
irritation, pain on urination, vaginal pain associated with sexual activity, or vaginal bleeding 
associated with sexual activity. The inclusion criteria did not have a minimum severity 
requirement for VVA symptoms. 
After informed consent, we recorded age, age of menopause onset, parity and body 
mass index (BMI) for all enrolled patients. All patients underwent VHIS evaluation, 
performed always by the same gynecologist in order to avoid inter-observer variability, and 
filled the FSFI questionnaire. Following baseline evaluation (T0), all the enrolled women 
underwent 15 days of vaginal treatment with one application (approximately 2 ml) per day of 
the new vaginal cream (Refeel, I.D.I. Pharma, Italy) containing visnadine (0.30%), 
prenylflavonoids (0.10%) and bovine colostrum (1%). The total volume of the cream 
administered during the treatment was 30 ml. The pH of the cream was 5.5. The cream was 
administered through single-use vaginal dispensers/applicators in the morning, after intimate 
cleansing. Any patient taking less than 80% of the allocated dose of study drug was regarded 
as noncompliant and excluded from the study. The study drug was offered for free and none 
of the enrolled patients were paid to enter or continue the study. Following treatment (T1), all 
patients were evaluated using VHIS and FSFI, all side effects recorded and an independent 
data safety and monitoring committee evaluated the results of the study. 
 
Results 
 A total of 54 women who met the inclusion/exclusion criteria and signed informed 
consent were enrolled into the study. Since 3 patients discontinued the intervention and 4 were 
lost to follow-up, the analysis was limited to 47 women. All of them declared that they took at 
least 90% of the allocated dose of study drug. Mean age was 56.5 ± 4.3 years, mean age at 
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menopause was 49.7 ± 1.8 years, mean BMI was 27.8 ± 1.7, mean parity was 1.7 ± 0.9. 
 Following treatment there was a significant improvement of all VHIS parameters 
(Table 1) including, elasticity, fluid volume and consistency, pH, epithelial integrity and 
moisture, as well as VHIS total score (p<0.0001). 
 Pre- and post-treatment analyses of FSFI domains showed a significant improvement 
(Table 1) of 4 FSFI domains (lubrication, orgasm, satisfaction and pain), whereas no 
statistical differences were noted for the remaining 2 domains (desire, arousal) (p=0.31 and 
p=0.036, respectively). In addition, the FSFI total score significantly increased (p=0.001) 
between pre-treatment (22.8 ± 4.2) and post-treatment (25.2 ± 2.4) phases. None of the 
subjects reported any local or systemic side effect whiles on the treatment. 
 
Discussion 
 Postmenopause is characterized by several hormonal and metabolic changes, which 
frequently compromise the quality of life of women. In particular, a number of menopause-
related symptoms and signs are derived as a result of severe lack of estrogen production [1, 
2].  
 Based on this information, we tested a new vaginal cream containing visnadine 
(0.30%), prenylflavonoids (0.10%) and bovine colostrum (1%) in a cohort of sexually active 
postmenopausal women affected by VVA. According to our preliminary data analysis, the 
vaginal cream was able to ameliorate both vaginal health and sexual quality, as documented 
by the significant increase of VHIS and FSFI parameters. Importantly, an excellent safety 
profile (no side effects during the study period) was noted.  
 To the best of our knowledge, this is the first single arm pilot study determining the 
effects of a mixture of visnadine, prenylfavanoids and bovine colostrum for the treatment of 
postmenopausal VVA. Nevertheless, several limitations of the study should be taken into 
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account during interpretation of our preliminary data: first of all, the sample size is limited as 
well as the follow-up, which do not allow to define whether the treatment’s effects will last 
for a longer period; second, it is not possible to ascertain the weight of each component of the 
cream in improving VVA and sexual wellbeing; third, the study design does not have a control 
arm allocated with placebo or no-treatment; fourth, we excluded 3 patients who discontinued 
the intervention, possibly enhancing the treatment effects. Despite these limitations, our 
preliminary data shows a potential beneficial effect of the new cream in regards to VHIS and 
FSFI in postmenopausal women with VVA. Since the limitations of this single arm pilot 
study, the new vaginal cream should be tested in a randomised controlled trial using a placebo 
cream without the active ingredients or current standard of care treatment. 
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